August

Analysis of the Intellectual Property behind Sanofi-Aventis' proposed acquisition of Genzyme

This week’s Patently Obvious report focuses on the patent holdings of Genzyme Corporation (NASDAQ:GENZ). On August 30th French drug maker Sanofi-Aventis SA (NYSE:SNY) went public with their offer to acquire Genzyme. The offer, at $69 dollars a share for a $18.5 billion total price, was rejected by Genzyme.

Sanofi-Aventis will have to fully consider the potential liabilities associated with owning Genzyme's intellectual property before increasing their bid. Genzyme has faced a slew of troubles recently and the cracks run deeper than the surface.

Intellectual Property Analysis of Interval Licensing’s U.S. Patent Nos. 6,788,314 and 6,034,652 referenced in Interval Licensing LLC v. eBay, Inc. et al

In August of 2010, Paul Allen, co-founder of Microsoft, initiated a lawsuit against 11 tech companies including Apple, Google, Facebook, Yahoo, AOL, YouTube, eBay, Netflix, OfficeMax, Office Depot, and Staples, alleging that they were in violation of patents granted to Interval Research in the 1990's while he was in a management role at that entity.

Home	M·CAM Financial	Global Innovation Commons
About	Strategic Innovation	Heritable Innovation Trust
Our Story	Innovation Literacy	Integral Trade
News	M·USE	All Patents Considered
Podcast	Patently Obvious	Integral Accounting
Management	Eastern District	Reports
Compass	Strategic Alliances	M·CAM Timeline
Odyssey	Helix	Epiphany